Patent application number | Description | Published |
20160103559 | GRAPHICAL USER INTERFACE FOR STATIC AND ADAPTIVE THRESHOLDS - Techniques are disclosed for providing a graphical user interface (GUI) for displaying and configuring adaptive or static thresholds for Key Performance Indicators (KPIs). The GUI may include one or more presentation schedules that may display threshold information associated with time policies. Each presentation schedule may include multiple time slots and span a portion of one or more time cycles. Some of the time slots may be associated with a specific time policy and may have a unifying appearance that distinguishes the time slots from timeslots associated with other time policies. The presentation schedules may arrange the time slots in a time grid arrangement (e.g., calendar grid view) or a graph arrangement with depictions (e.g., points, lines) that may illustrate KPI values and threshold markers that may illustrate the threshold values. | 04-14-2016 |
20160103838 | ANOMALY DETECTION - Techniques are disclosed for anomaly detection. A search query can be executed over a period of time to produce values for a key performance indicator (KPI), the search query defining the KPI and deriving a value indicative of the performance of a service at a point in time or during a period of time, the value derived from machine data pertaining to one or more entities that provide the service. A graphical user interface (GUI) enabling a user to indicate a sensitivity setting can be displayed. A user input indicating the sensitivity setting can be received via the GUI. Zero or more of the values as anomalies can be identified in consideration of the sensitivity setting indicated by the user input. A GUI including information related to the values identified as anomalies can be d | 04-14-2016 |
20160104076 | ADAPTIVE KEY PERFORMANCE INDICATOR THRESHOLDS - Techniques are disclosed for providing adaptive thresholding technology for Key Performance Indicators (KPIs). Adaptive thresholding technology may automatically assign new values or adjust existing values for one or more thresholds of one or more time policies. Assigning threshold values using adaptive thresholding may involve identifying training data (e.g., historical data, simulated data, or example data) for the time frames and analyzing the training data to identify variations within the data (e.g., patterns, distributions, trends). A threshold value may be determined based on the variations and may be assigned to one or more of the thresholds without additional user intervention. | 04-14-2016 |
Patent application number | Description | Published |
20090053763 | Tumor endothelial marker 7-alpha molecules and uses thereof - The present invention provides Tumor Endothelial Marker 7α (TEM7α) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM7α polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TEM7α polypeptides. | 02-26-2009 |
20090054323 | Specific Binding Agents of Human Angiopoietin-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 02-26-2009 |
20090191212 | Angiopoietin-2 Specific Binding Agents - Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. | 07-30-2009 |
20100286060 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 11-11-2010 |
20110311546 | Angiopoietin-2 specific binding agents - Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. | 12-22-2011 |
20120141499 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 06-07-2012 |
20130142799 | Angiopoietin-2 Specific Binding Agents - Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. | 06-06-2013 |
20130158234 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 06-20-2013 |
20130336992 | ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 AND USES THEREOF - Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. | 12-19-2013 |
20140275479 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 09-18-2014 |